Atreca (BCEL) Plans Underwritten Public Offering of Class A Common Stock

Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced that it intends to offer shares of its Class A Common Stock (the “Shares”) in an underwritten public offering. In connection with the offering, Atreca expects to grant the underwriters a 30-day option to purchase additional shares of its Class A Common Stock. All of the Shares will be offered by Atreca.

Cowen and Company, LLC, Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.

A shelf registration statement relating to the offered Shares was filed with the Securities and Exchange Commission (SEC) on July 2, 2020, and was declared effective on July 10, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov.

You May Also Be Interested In

• HIVE's BUZZ HPC signs $350M five-year AI cloud services deal
• Realty Income closes $1B convertible notes offering
• bioAffinity Technologies closes $4M private placement offering